News
News
Press Release
Shiga University of Medical Science and Sysmex Identify Factors Associated with Blood-Based Biomarkers Related to Alzheimer's Disease in General Japanese Men
Shiga University of Medical Science
Sysmex Corporation
In the Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA), which is led by the NCD Epidemiology Research Center of Shiga University of Medical Science (SUMS), a research article has been published in the Journal of Alzheimer’s Disease as a collaborative study by the SUMS NCD Epidemiology Research Center, the SUMS Molecular Neuroscience Research Center, and Sysmex Corporation. The article examines Alzheimer’s disease-related blood biomarkers and the factors associated with them.
This study clarified the associations between blood-based biomarkers and age, renal function, and cognitive function in a general population, providing important evidence for the implementation of blood-based early dementia risk testing in society.
POINT
|
|
The blood-based biomarker measurement technology, which assesses dementia risk from a simple blood test, is expected to serve as a new testing approach that can be used even before the onset of symptoms because it is minimally invasive and easy to perform. | |
|
|
Most previous studies have mainly targeted patients who already have cognitive impairment, and large-scale studies in the general population have been limited. Studies conducted in the general population are important for advancing the social implementation of blood-based biomarkers. | |
|
|
Plasma concentrations of Alzheimer's disease (AD)-related biomarkers—including amyloid beta 40 (Aβ40), Aβ42, total tau (T-tau), phosphorylated tau181 (P-tau181), and NfL—were measured in 845 randomly selected men aged 40 years or older from Kusatsu City, Shiga Prefecture. | |
|
|
All AD-related biomarker levels were found to be higher at older ages and with lower renal function (eGFR). Among the measured markers, higher T-tau and P-tau181 levels were associated with lower cognitive function. The Aβ42/Aβ40 ratio, a biomarker of amyloid deposition in the brain, decreases with advancing age (indicating amyloid positivity), however, it was not associated with eGFR, suggesting that the ratio may be less affected by renal function. | |
|
|
While blood-based biomarkers are a promising method for detecting changes in the pre-symptomatic stage, the findings indicate that their values need to be interpreted carefully, taking into account the influence of age and renal function. | |
|
|
In this study, measurements were performed using Sysmex Corporation's Automated Immunoassay System HISCL™-5000.* | |
| * Medical Device Marketing Authorization Number in Japan: 28B1X10014000011 |
Article Information
| Journal : | Journal of Alzheimer’s Disease. 2026 (Volume 109, Issue 4: 1702-1712) | |
| Title : | Plasma biomarkers for Alzheimer’s disease in middle-aged and older Japanese men: A population-based cross-sectional study | |
| Presented by : | Masaki Nakano, Keiko Kondo, Kengo Ishiki, Mohammad Moniruzzaman, Yachiyo Mitsuishi1, Aya Kadota, Shunsuke Watanabe, Kazuto Yamashita, Masahiro Miura, Shigeki Iwanaga, Toshiyuki Sato, Masaki Nishimura and Katsuyuki Miura; for the SESSA Research Group |
▶ For more information about this article. *Japanese only (https://www.sysmex.co.jp/news/2026/pdf/260303.pdf)
About Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, is a global leader in in vitro diagnostics. Since its foundation in 1968, Sysmex has focused on diagnostics as the core of its business, and today, it supports the health of people in over 190 countries and regions worldwide. Sysmex continues to innovate in diagnostics, and to collaboratively create unique values in the areas of personalized medicine and novel treatments, under its long-term vision of "Together for a better healthcare journey." Through its unique technology, solutions, and co-creation with various partners, Sysmex delivers new value and addresses the universal desire of people to live longer and healthier lives.
* "Healthcare journey" is a trademark of Sysmex Corporation, registered in Japan.
For more information about Sysmex, please visit www.sysmex.co.jp/en/.
FOLLOW US 
- The purpose of this news release is to communicate our business activities to our stakeholders. It may or may not include information about Sysmex's products or their research and development, but this is not intended for promotion, advertising or medical advice. The information contained in this news release is current as of the date of the announcement but may be subject to change without prior notice.